<i>BCL2A1</i> is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
Rizwan Haq(Ontario Institute for Cancer Research), David E. Fisher(Dana-Farber Cancer Institute)
Cited by 224
Related Papers
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|592
c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi
|Genes & Development|2000|517
Melanoma: from mutations to medicine
|Genes & Development|2012|476
Major Response to Imatinib Mesylate in <i>KIT</i>-Mutated Melanoma
|Journal of Clinical Oncology|2008|414
MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma
|American Journal Of Pathology|2003|311